Prime Med, Bristol Myers Squibb to Develop and Commercialize T-Cell Therapies

 Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies  

Prime Medicine to Receive $110 Million Upfront, with Potential for More Than $3.5 Billion in Milestones, Including $1.4 Billion in Development Milestones and More Than $2.1 Billion in Commercialization Milestones

https://www.globenewswire.com/news-release/2024/09/30/2955067/0/en/Prime-Medicine-Announces-Strategic-Research-Collaboration-and-License-Agreement-with-Bristol-Myers-Squibb-to-Develop-and-Commercialize-Multiple-Prime-Edited-Ex-Vivo-T-Cell-Therapie.html